β-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: Role in the regulation of response to somatostatin analogue treatment in patients with acromegaly

Endocrinology

Volumn 154, Issue 12, 2013, Pages 4715-4725

  Gatto, Federico ^a   Feelders, Richard ^a   Van Der Pas, Rob ^a   Kros, Johan M ^a   Dogan, Fadime ^a   Van Koetsveld, Peter M ^a   Van Der Lelij, Aart Jan ^a   Neggers, Sebastian J C M M ^a   Minuto, Francesco ^b   De Herder, Wouter ^a   Lamberts, Steven W J ^a   Ferone, Diego ^b   Hofland, Leo J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN 1; BETA ARRESTIN 2; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE 2; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; BETA ARRESTIN; MESSENGER RNA; RETINA S ANTIGEN; SOMATOSTATIN;

ACROMEGALY; ADULT; AGED; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; FEMALE; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HUMAN CELL; HYPOPHYSIS ADENOMA; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF DETECTION; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; ANALOGS AND DERIVATIVES; ANIMAL; CELL CULTURE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HYPOPHYSIS TUMOR; METABOLISM; MIDDLE AGED; PHYSIOLOGY; SIGNAL TRANSDUCTION; YOUNG ADULT;

ACROMEGALY; ADULT; AGED; ANIMALS; ARRESTINS; CELLS, CULTURED; FEMALE; G-PROTEIN-COUPLED RECEPTOR KINASE 2; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; PITUITARY NEOPLASMS; RATS; RNA, MESSENGER; SIGNAL TRANSDUCTION; SOMATOSTATIN; YOUNG ADULT;

EID: 84888253134     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1672     Document Type: Article

References (34)

1. Barlier A, Gunz G, Zamora AJ, et al. Pronostic and therapeutic consequences of Gs α mutations in somatotroph adenomas. J Clin Endocrinol Metab. 1998;83:1604-1610.
2. Fougner SL, Lekva T, Borota OC, Hald JK, Bollerslev J, Berg JP. The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J Clin Endocrinol Metab. 2010;95:2334-2342.
3. Fougner SL, Bollerslev J, Latif F, et al. Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. J Clin Endocrinol Metab. 2008;93:1211-1216.
4. Tulipano G, Stumm R, Pfeiffer M, Kreienkamp HJ, Höllt V, Schulz S. Differential β-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J Biol Chem. 2004;279:21374-21382.
5. Kao YJ, Ghosh M, Schonbrunn A. Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists. Mol Endocrinol. 2011;25:1040-1054.
6. Oakley RH, Laporte SA, Holt JA, Caron MG, Barak LS. Differential affinities of visual arrestin, β arrestin1, and β arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem. 2000;275:17201-17210.
7. Tulipano G, Schulz S. Novel insights in somatostatin receptor physiology. Eur J Endocrinol. 2007;156(suppl 1):S3-S11.
8. de Herder WW, Taal HR, Uitterlinden P, Feelders RA, Janssen JA, van der Lely AJ. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. Eur J Endocrinol. 2005;153:67-71.
9. de Bruin C, Hanson JM, Meij BP, et al. Expression and functional analysis of dopamine receptor subtype 2 and somatostatin receptor subtypes in canine cushing's disease. Endocrinology. 2008;149:4357-4366.
10. Hofland LJ, van der Hoek J, van Koetsveld PM, et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab. 2004;89:1577-1585.
11. de Bruin C, Pereira AM, Feelders RA, et al. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab. 2009;94:1118-1124.
12. Oosterom R, Blaauw G, Singh R, Verleun T, Lamberts SW. Isolation of large numbers of dispersed human pituitary adenoma cells obtained by aspiration. J Endocrinol Invest. 1984;7:307-311.
13. Lamberts SW, Verleun T, Hofland L, Del Pozo E. A comparison between the effects of SMS 201-995, bromocriptine and a combination of both drugs on hormone release by the cultured pituitary tumour cells of acromegalic patients. Clin Endocrinol (Oxf). 1987;27:11-23.
14. Jaquet P, Saveanu A, Gunz G, et al. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab. 2000;85:781-792.
15. Taboada GF, Luque RM, Bastos W, et al. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol. 2007;156:65-74.
16. Jaquet P, Ouafik L, Saveanu A, et al. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab. 1999;84:3268-3276.
17. Plöckinger U, Albrecht S, Mawrin C, et al. Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. J Clin Endocrinol Metab. 2008;93:1203-1210.
18. Giustina A, Chanson P, Bronstein MD, et al. Aconsensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95:3141-3148.
19. Ferone D, de Herder WW, Pivonello R, et al. Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab. 2008;93:1412-1417.
20. Gatto F, Feelders RA, van der Pas R, et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2013;98:E66-E71.
21. Wildemberg LE, Neto LV, Costa DF, et al. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. J Endocrinol Invest. 2013;36:38-43.
22. Gadelha MR, Kasuki L, Korbonits M. Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab. 2012;24:238-246.
23. Shenoy SK, Lefkowitz RJ. β-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol Sci. 2011;32:521-533.
24. Lombardi MS, Kavelaars A, Heijnen CJ. Role and modulation of G protein-coupled receptor signaling in inflammatory processes. Crit Rev Immunol. 2002;22:141-163.
25. Attramadal H, Arriza JL, Aoki C, et al. β-Arrestin2, a novel member of the arrestin/β-arrestin gene family. J Biol Chem. 1992;267:17882-17890.
26. Neill JD, Duck LW, Musgrove LC, Sellers JC. Potential regulatory roles for G protein-coupled receptor kinases and β-arrestins in go-nadotropin-releasing hormone receptor signaling. Endocrinology. 1998;139:1781-1788.
27. Brasselet S, Guillen S, Vincent JP, Mazella J. β-Arrestin is involved in the desensitization but not in the internalization of the somatostatin receptor 2A expressed in CHO cells. FEBS Lett. 2002;516:124-128.
28. Mundell SJ, Benovic JL. Selective regulation of endogenous G protein-coupled receptors by arrestins in HEK293 cells. J Biol Chem. 2000;275:12900-12908.
29. Penela P, Elorza A, Sarnago S, Mayor F Jr. β-Arrestin- and c-Src-dependent degradation of G-protein-coupled receptor kinase 2. EMBO J. 2001;20:5129-5138.
30. Penela P, Ribas C, Mayor F Jr. Mechanisms of regulation of the expression and function of Gprotein-coupled receptor kinases. Cell Signal. 2003;15:973-981.
31. Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab. 2009;94:654-661.
32. Pöll F, Lehmann D, Illing S, et al. Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. Mol Endocrinol. 2010;24:436-446.
33. Petersenn S, Schopohl J, Barkan A, et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab. 2010;95:2781-2789.
34. Petersenn S, Farrall AJ, Block C, et al. Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an openended, multicenter, phase II extension study. [published online March 26, 2013] Pituitary. doi:10.1007/s11102-013-0478-0.